Zydus Cadila to start phase 1 clinical trials on ZYH2

By Elaine Rigoli

Tampa, Fla., July 27 - Zydus Cadila is starting a phase 1 clinical trial on its new molecular entity ZYH2, which the company said may improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia and also lowers elevated lipid levels.

The company said Indians are genetically more susceptible to diabetes and the World Health Organization predicts the number of diabetics in India would go up to 40 million by 2010 and 74 million by 2025, making it the diabetes capital of the world.

Zydus Cadila is a pharmaceutical company located in Ahmedabad, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.